Your browser doesn't support javascript.
Ursodeoxycholic acid as a candidate therapeutic to alleviate and/or prevent COVID-19-associated cytokine storm.
Abdulrab, Saleem; Al-Maweri, Sadeq; Halboub, Esam.
  • Abdulrab S; Madinat Khalifa Health Center, Primary Health Care Corporation, Doha, Qatar; Ministry of Public Health and Population, Sana'a, Yemen. Electronic address: dentistsalim@gmail.com.
  • Al-Maweri S; Department of Oral Medicine and Diagnostic Science, Al Farabi Colleges, Riyadh, Saudi Arabia. Electronic address: sadali05@hotmail.com.
  • Halboub E; Department of Maxillofacial Surgery and Diagnostic Sciences, College of Dentistry, Jazan University, Jazan, Saudi Arabia; Department of Oral Medicine, Oral Pathology and Oral Radiology, Faculty of Dentistry, Sana'a University, Sana'a, Yemen. Electronic address: mhelboub@gmail.com.
Med Hypotheses ; 143: 109897, 2020 10.
Article in English | MEDLINE | ID: covidwho-437454
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Ursodeoxycholic Acid / Coronavirus Infections / Cytokine Release Syndrome Limits: Humans Language: English Journal: Med Hypotheses Year: 2020 Document Type: Article

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Ursodeoxycholic Acid / Coronavirus Infections / Cytokine Release Syndrome Limits: Humans Language: English Journal: Med Hypotheses Year: 2020 Document Type: Article